2015
DOI: 10.1007/s00277-015-2422-z
|View full text |Cite
|
Sign up to set email alerts
|

Factors associated with hematopoietic cell transplantation (HCT) among patients in a population-based study of myelodysplastic syndrome (MDS) in Minnesota

Abstract: Myelodysplastic syndrome (MDS) is a clonal hematopoietic stem cell disorder characterized by dysplastic changes in the bone marrow, ineffective erythropoiesis and an increased risk of developing acute myeloid leukemia. Treatment planning for patients with MDS is a complex process and we sought to better characterize HCT outcomes and the factors that play into decision-making regarding referral of adults with MDS for definitive therapy with hematopoietic cell transplantation (HCT). Patients enrolled in a popula… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

2
3
1

Year Published

2016
2016
2023
2023

Publication Types

Select...
7

Relationship

0
7

Authors

Journals

citations
Cited by 8 publications
(6 citation statements)
references
References 24 publications
2
3
1
Order By: Relevance
“…The findings on mortality are in line with the previous reported SEER data from the United States 11 . On a similar topic, three American studies on SCT have also found associations between survival among transplanted MDS patients and income 26‐28 . While it could be speculated that the differences in the American studies derive from differences in health insurance policies, our study was performed in a country where nearly all specialised care and medications are publically funded with minimal cost to the individual patient, and healthcare on equal conditions for the entire population is mandated by law.…”
Section: Discussionsupporting
confidence: 89%
“…The findings on mortality are in line with the previous reported SEER data from the United States 11 . On a similar topic, three American studies on SCT have also found associations between survival among transplanted MDS patients and income 26‐28 . While it could be speculated that the differences in the American studies derive from differences in health insurance policies, our study was performed in a country where nearly all specialised care and medications are publically funded with minimal cost to the individual patient, and healthcare on equal conditions for the entire population is mandated by law.…”
Section: Discussionsupporting
confidence: 89%
“…36 Indeed, a recent population-based study in Minnesota found that, when comparing 33 MDS patients who underwent HCT to 32 age-and risk-matched MDS patient controls, HCT patients were more likely to have a college degree and have a higher income (P = 0.02 for both factors). 17 This disparity is likely due to the fact that referral to tertiary centers such as one of our two facilities is necessary for the procedure; however, our findings suggest that even after such a referral occurs, rates of potentially curative RIC HCT could still be improved. Patient factors, physician QOL and RIC HCT for MDS A El-Jawahri et al factors and donor availability all likely have roles in this disparity.…”
Section: Discussioncontrasting
confidence: 48%
“…Candidate factors that likely impact this decision-making process include patient's age, disease course and severity, 17 QOL, patients' preferences with respect to the relative utility of being cured versus risk of transplant and burden of prolonged treatments, donor availability, and clinicians' perception of patients' QOL and functional status. Elucidating these factors is instrumental to address barriers to RIC HCT in this population with potentially curable disease, and to delineate important considerations that may be overlooked in the decision-making process.…”
Section: Introductionmentioning
confidence: 99%
“… 4 , 5 Therapeutic strategies for low-risk MDS include red blood cell (RBC) infusion and iron chelation therapy, the combined use of hematopoietic growth factors and immunosuppressive agents, and androgen-assisted therapy, but the response to these treatments is unsatisfactory. 5 7 …”
Section: Introductionmentioning
confidence: 99%
“…4,5 Therapeutic strategies for low-risk MDS include red blood cell (RBC) infusion and iron chelation therapy, the combined use of hematopoietic growth factors and immunosuppressive agents, and androgen-assisted therapy, but the response to these treatments is unsatisfactory. [5][6][7] Numerous studies have shown that glutathione peroxidase is involved in the development and progression of many tumors. 8,9 Glutathione peroxidase 3 (GPX3) is the most widely studied member of the GPX family.…”
Section: Introductionmentioning
confidence: 99%